Merck & Co., Inc. Form 10-K for fiscal year ended December 31, 2025 (Item 1, Patents; MD&A) (2026)

Government Record · Merck & Co., Inc. (filed with the U.S. Securities and Exchange Commission) · February 2026

Merck's 10-K states that the primary Keytruda compound patent expires in December 2028, that two further composition-of-matter patents run to May and November 2029, and gives Keytruda expiration years of 2028 (US), 2031 (EU), 2032-2033 (Japan), 2028 (China).

while two patents in the Keytruda composition of matter patent family expire in May and November of 2029, respectively, the Company expects these patents to be the subject of litigation and, thus, biosimilar competition could begin in December 2028 when the primary compound patent expires.

Item 1 / MD&A (HTML filing; patent table sits at printed p. 13)

Merck's 10-K states that the primary Keytruda compound patent expires in December 2028, that two further composition-of-matter patents run to May and November 2029, and gives Keytruda expiration years of 2028 (US), 2031 (EU), 2032-2033 (Japan), 2028 (China). Funder/conflicts: issuer's own filing (management's characterization; no independent audit of patent dates). Maker: Merck. Comparator: n/a. The 10-K does NOT disclose a patent count for Keytruda – the prompt's request for 'its patent count' is not answered by this document. On the subcutaneous strategy, the same filing refers to 'Keytruda Qlex' and to royalties continuing on 'net sales of Keytruda and Keytruda Qlex'. Study type: regulatory record.